Status:
UNKNOWN
Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT
Lead Sponsor:
Chinese PLA General Hospital
Conditions:
aGVHD
cGVHD
Eligibility:
All Genders
14-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the efficacy and safety of combined ATG #antithymocyte globulin # regimen (5mg/kg divided from day -5 to day -2) for aGVHD(acute graft-versus-host disease ) p...
Detailed Description
Transplantation with G-CSF #Granulocyte colony stimulating factor #mobilized peripheral blood stem cell (PBSCT) has been a stable transplant setting with matched sibling donor transplantation. Unmanip...
Eligibility Criteria
Inclusion
- Patients were aged from 14 to 65 years;
- Patients were diagnosed of acute leukemia or MDS;
- There were indications of MSD-PBSCT for these patients;
- Patients without any uncontrolled infections or without severe pulmonary, renal, hepatic or cardiac diseases.
Exclusion
- Patients with any uncontrolled infections or with severe pulmonary,renal, hepatic or cardiac diseases;
- AML patients with t (15;17).
Key Trial Info
Start Date :
February 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05214066
Start Date
February 1 2019
End Date
August 1 2022
Last Update
February 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853